Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30739044 | 0.91 | CACNA1H (0.46) | TSHRMAPK10KDM4AALDH1A1NSD2 | |
| SCHEMBL22828999 | 0.83 | ALDH1A1 (0.48) | TSHRMAPK10ALDH1A1NSD2L3MBTL1 | |
| SCHEMBL31433016 | 0.83 | MEN1 (0.50) | TSHRMAPK10ALDH1A1 | |
| SCHEMBL2798794 | 0.82 | KDM4A (0.43) | KDM4ANSD2L3MBTL1GLSNAMPT | |
| SCHEMBL22828610 | 0.81 | DYRK1A (0.44) | TSHRMAPK10ALDH1A1NSD2L3MBTL1 | |
| SCHEMBL13055397 | 0.79 | KDM4A (0.51) | TSHRKDM4AL3MBTL1GLSNAMPT | |
| SCHEMBL26075754 | 0.78 | CACNA1H (0.49) | NSD2 | |
| SCHEMBL2574214 | 0.77 | CYP1A2 (0.56) | TSHRALDH1A1 | |
| SCHEMBL30545886 | 0.76 | CACNA1H (0.44) | ALDH1A1DRD2CTSSCTSK | |
| SCHEMBL26076675 | 0.76 | CACNA1H (0.44) | ALDH1A1DRD2CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129016-A1 | PHOTOREDOX METHODS FOR RADIOCYANATION OF ARENES AND USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129016-A1 | PHOTOREDOX METHODS FOR RADIOCYANATION OF ARENES AND USE THEREOF | RCC2, PPOX, FTO | TSHR 1853/4885MAPK10 3319/4885KDM4A 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.